null

Natalizumab (Anti-CD49D / Integrin alpha 4) Biosimilar In Vivo Antibody

SKU:
IVMB0207
Product Type:
Biosimilar In Vivo Antibody
Protein:
CD49D
Clone:
Hu114
Isotype:
IgG1 kappa
Reactivity:
Human
Synonyms:
CD49D, alpha 4 subunit of VLA-4 receptor, ITGA4, Integrin alpha-IV
$299 - $8,135
Frequently bought together:

Description

system_update_altDatasheet
Product Name:Natalizumab (Anti-CD49D / Integrin alpha 4) Biosimilar In Vivo Antibody
Product Code:IVMB0207
Clone:Hu114
Protein:CD49D
Product Type:Biosimilar Recombinant Human Monoclonal Antibody
Synonyms:CD49D, alpha 4 subunit of VLA-4 receptor, ITGA4, Integrin alpha-IV
Isotype:Human IgG1κ
Reactivity:Human
Immunogen:RAMOS cell line injected into mice.
Applications:B, FC
Formulation:This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:< 1.0 EU/mg as determined by the LAL method
Purity:≥95% monomer by analytical SEC
Preparation:Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Applications:B, FC
Recommended Usage:FC
The suggested concentration for Natalizumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 µg per 106 in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.
Reactivity:Human
Specificity:This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Natalizumab. Natalizumab binds to the alpha 4 subunit of α4?1 and α4?7 integrins. This product is for research use only.
Antigen Distribution:CD49D is a subunit of the integrin VLA-4, which is expressed on the cell surfaces of stem cells, progenitor cells, T and B cells, monocytes, natural killer cells, eosinophils, and neutrophils.
Immunogen:RAMOS cell line injected into mice.
Concentration:≥ 5.0 mg/ml
Endotoxin Level:< 1.0 EU/mg as determined by the LAL method
Purity:≥95% monomer by analytical SEC
Formulation:This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Preparation:Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Natalizumab is characterized as a disease-modifying therapy for multiple sclerosis (a disease of the central nervous system (CNS)), and inflammatory bowel disease. It works by inhibiting the migration of leukocytes to inflammation sites. The VCAM-1 and α4?1-integrin interaction is necessary for leukocyte adhesion, firm attachment, and transmigration across the blood-brain barrier into the CNS. Natalizumab, a recombinant, humanized antibody, binds to α4?1 -integrin and blocks its interaction with VCAM-1. Hence, leukocyte migration into brain tissue is inhibited, thereby reducing inflammation and preventing the formation of multiple sclerosis lesions.1 Inflammation in the gut pertaining to inflammatory bowel disease can be controlled in a similar fashion. Blocking α4?7-integrin with a humanized, monoclonal antibody, specific to the α4?7 heterodimer inhibits the migration of leukocytes into the inflamed intestinal tissue, thus, reducing inflammation in the gut.2 This cost-effective, research-grade Anti-Human CD49D (Natalizumab) utilizes the same variable regions from the therapeutic antibody Natalizumab making it ideal for research projects.
Protein:CD49D
Research Area:Cell Adhesion, Cell Biology, Immunology, Innate Immunity

Related Products